NCT02514460

Brief Summary

This is a randomized study comparing stent and plaque excision systems in treatment of lower limb (superficial femoral or popliteal artery) ischemia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

July 31, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 3, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
Last Updated

July 13, 2016

Status Verified

December 1, 2015

Enrollment Period

2.2 years

First QC Date

July 31, 2015

Last Update Submit

July 11, 2016

Conditions

Keywords

stentsatherectomyfemoral arterypopliteal artery

Outcome Measures

Primary Outcomes (2)

  • 12-month Primary Patency Rate

    Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis \>50% with a peak systolic velocity ratio \>2.4 as measured by Duplex ultrasound.

    12 months

  • 12-month Limb Salvage Rate

    Limb Salvage is defined as the freedom from secondary major amputation

    12 months

Secondary Outcomes (3)

  • Index Limb Ischemia at 6-month Follow up

    6 months

  • Index Limb Ischemia at 12-month Follow up

    12 months

  • Major Adverse Events at 12-month Post Procedure

    12 months

Study Arms (2)

Intervention: Stents

ACTIVE COMPARATOR

Stents group

Device: Stent

Intervention: Atherectomy

ACTIVE COMPARATOR

Direct Atherectomy group

Device: plaque excision system

Interventions

Intervention: Atherectomy
StentDEVICE
Intervention: Stents

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provides written informed consent Willing to comply with follow-up evaluations at specified times Has claudication or rest pain due to peripheral arterial disease Disease located within the femoropopliteal artery Patient has a de novo or restenotic lesion(s) with \>50% stenosis documented angiographically and no prior stent in the target lesion.
  • Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.

You may not qualify if:

  • Previously implanted stent(s) or stent graft(s) in target leg Life expectancy less than 12 months Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days. Receiving dialysis or immunosuppressant therapy. Recent stroke within past 90 days. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot be medically managed.
  • Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6) Serum creatinine level \>/= 2.5 mg/dl at time of screening visit Known or suspected active infection at the time of the procedure Bleeding diathesis Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
  • Patient is known to be pregnant, incarcerated, mentally incompetent, and/or alcohol or drug abuser.
  • Patient is currently participating in any other investigational drug or medical device study that has not completed primary endpoint(s) evaluation or clinically interferes with the endpoints from this study or future participation in such studies prior to the completion of this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gu Yong Quan

Beijing, Beijing Municipality, 100053, China

Location

Related Publications (1)

  • Yongquan G, Lianrui G, Lixing Q, Xuefeng L, Zhu T, Shijun C, Yingfeng W, Jianming G, Jian Z, Zhonggao W. Plaque excision in the management of lower-limb ischemia of atherosclerosis and in-stent restenosis with the SilverHawk atherectomy catheter. Int Angiol. 2013 Aug;32(4):362-7.

    PMID: 23822938BACKGROUND

MeSH Terms

Conditions

AtherosclerosisIschemia

Interventions

Stents

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Prostheses and ImplantsEquipment and Supplies

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2015

First Posted

August 3, 2015

Study Start

January 1, 2014

Primary Completion

March 1, 2016

Study Completion

April 1, 2016

Last Updated

July 13, 2016

Record last verified: 2015-12

Locations